Biocon Biologics concludes integration of acquired Biosimilars business in 120 countries
10+ emerging markets, Japan & ANZ transition in final phase
10+ emerging markets, Japan & ANZ transition in final phase
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics
Subscribe To Our Newsletter & Stay Updated